Core Insights - Annexon, Inc. is advancing targeted immunotherapies for neuroinflammatory diseases, with significant milestones expected in 2026, including pivotal data for vonaprument and tanruprubart [1][2][3] Company Developments - Vonaprument is positioned to be the first vision-preserving therapy for geographic atrophy (GA), a major cause of blindness affecting over 8 million patients globally [3][4] - The Phase 3 ARCHER II trial for vonaprument has completed enrollment with 659 patients, focusing on visual acuity as the primary endpoint [3][7] - Tanruprubart has been filed for Marketing Authorization Application (MAA) in Europe, aiming to be the first targeted fast-acting therapy for Guillain-Barré Syndrome (GBS), impacting approximately 150,000 people annually [4][6] - ANX1502 is advancing as the first oral C1 inhibitor for autoimmune diseases, with proof-of-concept data anticipated in 2026 [5][6] Financial Overview - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments totaling approximately $238.3 million, providing a runway into the second half of 2027 [1][7] - Research and development (R&D) expenses for Q4 2025 were $42.7 million, with a total of $184.7 million for the year, reflecting increased investment in late-stage programs [7][8] - General and administrative (G&A) expenses were $7.6 million for Q4 2025, showing a decrease from the previous year, indicating improved corporate efficiencies [7][8] Strategic Focus - The company is leveraging its scientific platform to develop therapies that target neuroinflammation at its source, with a focus on the C1q pathway [2][8] - The ongoing FORWARD study in the U.S. and Europe aims to broaden the experience with tanruprubart and support a planned Biologics License Application (BLA) submission in 2026 [3][7] - The company hosted an Investor Day in March 2026, showcasing the differentiated mechanism of action of vonaprument and its clinical development strategy [3]

Company Overview - Annexon is a biotech company based in Bayera, focusing on immunotherapy to treat neuroinflammatory diseases, with a mission to deliver transformative therapies for patients [2] - The company has two major registrational stage programs that target a market opportunity exceeding $10 billion and aim to treat over 10 million patients annually [2] Product Pipeline - The lead program is focused on dry Age-related Macular Degeneration (AMD) with geographic atrophy, which is a significant cause of blindness, and the drug candidate, vonaprument (ANX007), has shown substantial vision protection in affected patients [3] - The second drug candidate, tanruprubart, is aimed at treating Guillain-Barre syndrome [3]